Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential

被引:77
作者
Demidenko, Zoya N.
Blagosklonny, Mikhail V. [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC, Buffalo, NY 14263 USA
来源
AGING-US | 2009年 / 1卷 / 12期
关键词
cellular senescence; cellular hypertrophy; aging-suppression; rapamycin; mTOR; CELLS; ARREST; INHIBITION; SECRETION; RAPAMYCIN; PROTEIN; CANCER; LEADS;
D O I
10.18632/aging.100115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Development of agents that suppress aging (aging suppressants) requires quantification of cellular senescence. Cellular senescence in vitro is characterized by a large cell morphology and permanent loss of proliferative potential. When HT-1080 cells were arrested by p21, they continued to grow exponentially in size and became hypertrophic with a 15-fold increase in the protein content per cell. These changes were mirrored by accumulation of GFP ( driven by CMV promoter) per cell, which also served as a marker of cellular hypertrophy. Preservation of proliferative potential ( competence) was measured by an increase in live cell number, when p21 was switched off. While modestly decreasing hypertrophy in p21-arresrted cells, rapamycin considerably preserved competence, converting senescence into quiescence. Preservation of proliferative potential ( competence) correlated with inhibition of S6 phosphorylation by rapamycin. When p21 was switched off, competent cells, by resuming proliferation, became progressively less hypertrophic. Preservation of proliferative potential is a sensitive and quantitative measure of suppression of mTOR-driven senescence.
引用
收藏
页码:1008 / 1016
页数:9
相关论文
共 31 条
[1]   Control of senescence by CXCR2 and its ligands [J].
Acosta, Juan C. ;
O'Loghlen, Ana ;
Banito, Ana ;
Raguz, Selina ;
Gil, Jesus .
CELL CYCLE, 2008, 7 (19) :2956-2959
[2]   MicroRNAs miR-146a/b negatively modulate the senescence associated inflammatory mediators IL-6 and IL-8 [J].
Bhaumik, Dipa ;
Scott, Gary K. ;
Schokrpur, Shiruyeh ;
Patil, Christopher K. ;
Orjalo, Arturo V. ;
Rodier, Francis ;
Lithgow, Gordon J. ;
Campisi, Judith .
AGING-US, 2009, 1 (04) :402-411
[3]   Prevention of cancer by inhibiting aging [J].
Blagosklonny, Mikhail V. .
CANCER BIOLOGY & THERAPY, 2008, 7 (10) :1520-1524
[4]   Aging, stem cells, and mammalian target of rapamycin: A prospect of pharmacologic rejuvenation of aging stem cells [J].
Blagosklonny, Mikhail V. .
REJUVENATION RESEARCH, 2008, 11 (04) :801-808
[5]   An anti-aging drug today: from senescence-promoting genes to anti-aging pill [J].
Blagosklonny, Mikhail V. .
DRUG DISCOVERY TODAY, 2007, 12 (5-6) :218-224
[6]   Aging and immortality - Quasi-programmed senescence and its pharmacologic inhibition [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2006, 5 (18) :2087-2102
[7]   Cell senescence: Hypertrophic arrest beyond the restriction point [J].
Blagosklonny, Mikhail V. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) :592-597
[8]   Validation of anti-aging drugs by treating age-related diseases [J].
Blagosklonny, Mikhail V. .
AGING-US, 2009, 1 (03) :281-288
[9]   Aging-suppressants Cellular senescence (hyperactivation) and its pharmacologic deceleration [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2009, 8 (12) :1883-1887
[10]   Cell senescence and hypermitogenic arrest [J].
Blagosklonny, MV .
EMBO REPORTS, 2003, 4 (04) :358-362